Redmile Group’s Audentes Therapeutics, Inc BOLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-639,095
| Closed | -$38.2M | – | 78 |
|
|
2019
Q4 | $38.2M | Sell |
639,095
-2,323,560
| -78% | -$87.2M | 0.91% | 33 |
|
|
2019
Q3 | $83.2M | Sell |
2,962,655
-9,512
| -0.3% | -$325K | 2.79% | 12 |
|
|
2019
Q2 | $113M | Buy |
2,972,167
+236,900
| +9% | +$9.1M | 3.18% | 6 |
|
|
2019
Q1 | $107M | Buy |
2,735,267
+433,600
| +19% | +$12.4M | 3.12% | 9 |
|
|
2018
Q4 | $49.1M | Buy |
2,301,667
+58,311
| +3% | +$1.5M | 1.97% | 16 |
|
|
2018
Q3 | $88.8M | Buy |
2,243,356
+14,700
| +0.7% | +$548K | 2.73% | 10 |
|
|
2018
Q2 | $85.2M | Buy |
2,228,656
+920,130
| +70% | +$34.1M | 2.89% | 10 |
|
|
2018
Q1 | $39.3M | Buy |
1,308,526
+379,200
| +41% | +$12.8M | 1.52% | 25 |
|
|
2017
Q4 | $29M | Sell |
929,326
-360,006
| -28% | -$9.88M | 1.26% | 30 |
|
|
2017
Q3 | $36.1M | Sell |
1,289,332
-170,284
| -12% | -$3.7M | 1.78% | 18 |
|
|
2017
Q2 | $27.9M | Buy |
1,459,616
+638,780
| +78% | +$10.2M | 1.7% | 21 |
|
|
2017
Q1 | $14M | Sell |
820,836
-11,900
| -1% | -$192K | 0.91% | 42 |
|
|
2016
Q4 | $15.2M | Sell |
832,736
-83,890
| -9% | -$1.45M | 1.31% | 25 |
|
|
2016
Q3 | $14.9M | Buy |
+916,626
| New | +$13.9M | 1.19% | 27 |
|
Redmile Group's BOLD Position: Q1 2020 in Review
Redmile Group sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 639,095 shares — an estimated $38.2M sold.
Redmile Group first reported a position in BOLD in Q3 2016 and held it in 14 quarters. The position peaked at $113M in Q2 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.
- Redmile Group reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
- Redmile Group sold 639,095 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $38.2M.
- Redmile Group first reported a position in Audentes Therapeutics, Inc in Q3 2016 and held it in 14 quarters.
- Redmile Group's Audentes Therapeutics, Inc position peaked at $113M in Q2 2019.
- 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.
Based on Redmile Group's 13F filing for Q1 2020, filed 15 May 2020.